6 Quality Biotech Stocks on Sale Now
Who doesn't love a good sale? With the markets in turmoil and little idea when it will end, healthcare investors can seize the opportunity to snap up discounted shares of quality companies.
Here, I explore six attractive small and mid-cap biotechs with valuations greater than $5.5 billion. These established companies expect to generate revenue between $450 million and $2.4 billion in 2020. Yet due to market conditions, their stock prices have dropped between 10% and 35% this year.
Image Source: Getty Images.
Source Fool.com
